Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

Also called NCT02606357

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02606357
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Jordan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02606357. Allocation not applicable; no masking; primary purpose treatment. Start 2015-11-22 (actual); primary completion 2017-11-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Acronym
NEWLAN
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02606357
Content hash
a237f8139d2bc74a28cccb3ef589e5d277d5f00d2e814b4b19fae438e345b4b2